FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465408122> ?p ?o ?g. }

• W2465408122 endingPage "LBA1" @default.
• W2465408122 startingPage "LBA1" @default.
• W2465408122 abstract "LBA1 Background: Adjuvant endocrine therapy with AI vs T improves outcomes in postmenopausal HR+ BC. TEXT and SOFT were designed to test whether adjuvant AI improves outcomes in premenopausal women with HR+ BC treated with OFS (AI question) and to determine the value of OFS in women who remain premenopausal and are suitable for adjuvant T (OFS question). Methods: TEXT and SOFT, randomized phase 3 trials, enrolled 5,738 premenopausal women with HR+ early BC from Nov03 to Apr11 (2672 TEXT; 3066 SOFT). TEXT randomized women within 12wk of surgery to 5y E+OFS vs T+OFS; chemotherapy (CT) was optional and concurrent with OFS. SOFT randomized women to 5y E+OFS vs T+OFS vs T alone, either within 12wk of surgery if no CT planned, or within 8mo of completing (neo)adjuvant CT. OFS was by choice of 5y triptorelin, oophorectomy, or ovarian irradiation. The primary endpoint is disease-free survival (DFS: randomization until invasive local, regional, distant recurrence, or contralateral breast; 2nd malignancy; death). Due to low event rates, protocol amendments in 2011 changed the analysis plans to answer the AI question (E+OFS vs T+OFS) by joint analysis of TEXT and SOFT. By Q3’2013 with >5y median follow-up, 436 DFS events were projected, providing 84% power for HR=0.75 with E+OFS vs T+OFS (stratified logrank 2-sided α=0.05). Results: At 5.7y median follow-up, 514 (11%) DFS events were reported in the ITT population comparing E+OFS (n=2346) vs T+OFS (n=2344). Patients assigned E+OFS had significantly reduced DFS hazard (HR=0.72; 95% CI, 0.60-0.86; P=0.0002) vs T+OFS; 5y DFS was 91.1% vs 87.3%. Reductions were similar for secondary endpoints of BC-free interval (HR=0.66 (0.55-0.80) 5y BCFI 92.8% vs 88.8%) and distant recurrence-free interval (HR=0.78 (0.62-0.97)), though not overall survival (HR=1.14 (0.86-1.51)) at this early follow-up (194 (4%) deaths). Grade 3-4 targeted AEs were reported in 31% E+OFS vs 29% T+OFS patients. Conclusion: In premenopausal women with HR+ BC, adjuvant treatment with E+OFS significantly reduced the risk of recurrence compared to T+OFS. Clinical trial information: NCT00066703 / NCT00066690 ." @default.
• W2465408122 created "2016-07-22" @default.
• W2465408122 creator A5017334876 @default.
• W2465408122 creator A5020050040 @default.
• W2465408122 creator A5030358067 @default.
• W2465408122 creator A5034035919 @default.
• W2465408122 creator A5036344172 @default.
• W2465408122 creator A5040290360 @default.
• W2465408122 creator A5042046866 @default.
• W2465408122 creator A5046031005 @default.
• W2465408122 creator A5047644166 @default.
• W2465408122 creator A5052159944 @default.
• W2465408122 creator A5053376791 @default.
• W2465408122 creator A5055301443 @default.
• W2465408122 creator A5056530735 @default.
• W2465408122 creator A5056811246 @default.
• W2465408122 creator A5061327737 @default.
• W2465408122 creator A5063504632 @default.
• W2465408122 creator A5065306642 @default.
• W2465408122 creator A5069386928 @default.
• W2465408122 creator A5070351685 @default.
• W2465408122 creator A5073000306 @default.
• W2465408122 creator A5074162103 @default.
• W2465408122 creator A5080353398 @default.
• W2465408122 date "2014-06-20" @default.
• W2465408122 modified "2023-10-16" @default.
• W2465408122 title "Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials." @default.
• W2465408122 doi "https://doi.org/10.1200/jco.2014.32.18_suppl.lba1" @default.
• W2465408122 hasPublicationYear "2014" @default.
• W2465408122 type Work @default.
• W2465408122 sameAs 2465408122 @default.
• W2465408122 citedByCount "12" @default.
• W2465408122 countsByYear W24654081222014 @default.
• W2465408122 countsByYear W24654081222015 @default.
• W2465408122 countsByYear W24654081222016 @default.
• W2465408122 countsByYear W24654081222017 @default.
• W2465408122 countsByYear W24654081222018 @default.
• W2465408122 countsByYear W24654081222020 @default.
• W2465408122 crossrefType "journal-article" @default.
• W2465408122 hasAuthorship W2465408122A5017334876 @default.
• W2465408122 hasAuthorship W2465408122A5020050040 @default.
• W2465408122 hasAuthorship W2465408122A5030358067 @default.
• W2465408122 hasAuthorship W2465408122A5034035919 @default.
• W2465408122 hasAuthorship W2465408122A5036344172 @default.
• W2465408122 hasAuthorship W2465408122A5040290360 @default.
• W2465408122 hasAuthorship W2465408122A5042046866 @default.
• W2465408122 hasAuthorship W2465408122A5046031005 @default.
• W2465408122 hasAuthorship W2465408122A5047644166 @default.
• W2465408122 hasAuthorship W2465408122A5052159944 @default.
• W2465408122 hasAuthorship W2465408122A5053376791 @default.
• W2465408122 hasAuthorship W2465408122A5055301443 @default.
• W2465408122 hasAuthorship W2465408122A5056530735 @default.
• W2465408122 hasAuthorship W2465408122A5056811246 @default.
• W2465408122 hasAuthorship W2465408122A5061327737 @default.
• W2465408122 hasAuthorship W2465408122A5063504632 @default.
• W2465408122 hasAuthorship W2465408122A5065306642 @default.
• W2465408122 hasAuthorship W2465408122A5069386928 @default.
• W2465408122 hasAuthorship W2465408122A5070351685 @default.
• W2465408122 hasAuthorship W2465408122A5073000306 @default.
• W2465408122 hasAuthorship W2465408122A5074162103 @default.
• W2465408122 hasAuthorship W2465408122A5080353398 @default.
• W2465408122 hasConcept C121608353 @default.
• W2465408122 hasConcept C126322002 @default.
• W2465408122 hasConcept C143998085 @default.
• W2465408122 hasConcept C168563851 @default.
• W2465408122 hasConcept C203092338 @default.
• W2465408122 hasConcept C204243189 @default.
• W2465408122 hasConcept C207103383 @default.
• W2465408122 hasConcept C2775860665 @default.
• W2465408122 hasConcept C2776694085 @default.
• W2465408122 hasConcept C2777176818 @default.
• W2465408122 hasConcept C2777863537 @default.
• W2465408122 hasConcept C2778504769 @default.
• W2465408122 hasConcept C2778575703 @default.
• W2465408122 hasConcept C2778894405 @default.
• W2465408122 hasConcept C2779448150 @default.
• W2465408122 hasConcept C2780739268 @default.
• W2465408122 hasConcept C2908647359 @default.
• W2465408122 hasConcept C29456083 @default.
• W2465408122 hasConcept C44249647 @default.
• W2465408122 hasConcept C530470458 @default.
• W2465408122 hasConcept C71315377 @default.
• W2465408122 hasConcept C71924100 @default.
• W2465408122 hasConcept C99454951 @default.
• W2465408122 hasConceptScore W2465408122C121608353 @default.
• W2465408122 hasConceptScore W2465408122C126322002 @default.
• W2465408122 hasConceptScore W2465408122C143998085 @default.
• W2465408122 hasConceptScore W2465408122C168563851 @default.
• W2465408122 hasConceptScore W2465408122C203092338 @default.
• W2465408122 hasConceptScore W2465408122C204243189 @default.
• W2465408122 hasConceptScore W2465408122C207103383 @default.
• W2465408122 hasConceptScore W2465408122C2775860665 @default.
• W2465408122 hasConceptScore W2465408122C2776694085 @default.
• W2465408122 hasConceptScore W2465408122C2777176818 @default.
• W2465408122 hasConceptScore W2465408122C2777863537 @default.
• W2465408122 hasConceptScore W2465408122C2778504769 @default.
• W2465408122 hasConceptScore W2465408122C2778575703 @default.
• W2465408122 hasConceptScore W2465408122C2778894405 @default.

• next